FLC2 Antibody

What is FLRT2 and how does it function in biological systems?

FLRT2 (fibronectin leucine rich transmembrane protein 2) is a 74 kilodalton transmembrane protein that belongs to the leucine-rich repeat protein family. It may also be referred to as leucine-rich repeat transmembrane protein FLRT2 or fibronectin-like domain-containing leucine-rich transmembrane protein 2 . This protein plays significant roles in cell adhesion, cell migration, and axon guidance in neural development. FLRT2 contains an extracellular domain with leucine-rich repeats that facilitates protein-protein interactions, a transmembrane domain that anchors it to the cell membrane, and a cytoplasmic domain involved in intracellular signaling.

In research contexts, FLRT2 is often studied for its involvement in developmental processes, particularly neurodevelopment, and potential roles in pathological conditions including cancer progression and inflammatory responses. Understanding FLRT2's biological function provides the foundation for appropriately designing experiments using FLRT2 antibodies.

What are the principal applications of FLRT2 antibodies in research settings?

FLRT2 antibodies serve multiple critical functions in research protocols across various disciplines. Based on available data, FLRT2 antibodies can be employed in several validated applications:

These applications enable researchers to analyze FLRT2 expression patterns, localization, and potential functional roles in various experimental systems . When selecting an application, researchers should consider the specific experimental question, available sample types, and whether qualitative or quantitative data is required.

What species reactivity can be expected from commercially available FLRT2 antibodies?

Commercial FLRT2 antibodies demonstrate reactivity with samples from multiple species, allowing for cross-species comparative studies. Based on available product information, researchers can find antibodies with the following reactivity profiles:

• Human (Hu)

• Mouse (Ms)

• Rat (Rt)

• Bovine (Bv)

• Dog (Dg)

• Pig (Pg)

When designing experiments involving multiple species or translational studies between model organisms and humans, researchers should carefully verify the cross-reactivity of their selected antibody through validation studies or manufacturer data. Species-specific epitope differences may affect binding affinity and specificity across different experimental systems.

What is the optimal protocol for using FLRT2 antibodies in Western blot applications?

For Western blot applications using FLRT2 antibodies, researchers should follow this methodological framework:

• Sample Preparation:

  • Extract proteins using appropriate lysis buffers containing protease inhibitors

  • Determine protein concentration using BCA or Bradford assay

  • Prepare 20-40 μg protein per well in loading buffer containing SDS and DTT

• Gel Electrophoresis and Transfer:

  • Separate proteins on 8-10% SDS-PAGE (appropriate for the 74 kDa FLRT2 protein)

  • Transfer to PVDF membrane at 100V for 60-90 minutes in cold transfer buffer

• Antibody Incubation:

  • Block membrane with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

  • Incubate with primary FLRT2 antibody at recommended dilution (typically 1:100-1:500)

  • Incubate overnight at 4°C with gentle agitation

  • Wash 3× with TBST, 5 minutes each

  • Incubate with appropriate HRP-conjugated secondary antibody (1:2000-1:5000)

  • Wash 3× with TBST, 5 minutes each

• Detection and Analysis:

  • Apply ECL substrate and detect signal using appropriate imaging system

  • Expected FLRT2 band should appear at approximately 74 kDa

  • Include positive control samples with known FLRT2 expression

This protocol should be optimized for specific antibody characteristics and experimental conditions. Particular attention should be paid to blocking conditions and antibody dilutions to maximize specific binding while minimizing background.

How should researchers validate FLRT2 antibodies for novel applications?

Rigorous validation is essential when employing FLRT2 antibodies in novel applications. A comprehensive validation strategy includes:

• Positive and Negative Controls:

  • Use tissues/cells with known high FLRT2 expression as positive controls

  • Include samples with confirmed absence of FLRT2 expression as negative controls

  • Consider genetic approaches (knockdown/knockout) to generate validated negative controls

• Cross-Reactivity Assessment:

  • Test antibody against recombinant FLRT2 protein

  • Evaluate potential cross-reactivity with related proteins (e.g., other FLRT family members)

  • Perform peptide competition assays to confirm epitope specificity

• Multi-Method Confirmation:

  • Compare results across different detection methods (e.g., WB, IHC, IF)

  • Validate findings using alternative antibodies targeting different FLRT2 epitopes

  • Correlate protein detection with mRNA expression data

• Application-Specific Optimization:

  • Systematically test different fixation methods, antigen retrieval protocols, and antibody concentrations

  • Document optimal conditions in standard operating procedures

  • Assess reproducibility across different experimental batches

This systematic approach ensures that novel applications yield reliable, reproducible results while minimizing the risk of artifacts or misinterpretation of data.

What controls are essential when designing experiments with FLRT2 antibodies?

Proper experimental controls are critical for generating reliable data with FLRT2 antibodies. Essential controls include:

Additionally, when investigating FLRT2 in new experimental systems, researchers should consider genetic controls (siRNA knockdown or CRISPR knockout) to definitively establish antibody specificity. These comprehensive controls should be systematically incorporated into experimental design to ensure data integrity and accurate interpretation.

How can researchers distinguish between FLRT2 and related proteins or isoforms?

Distinguishing FLRT2 from related proteins (like FLRT1 and FLRT3) or potential isoforms requires specialized approaches:

• Epitope Selection Analysis:

  • Examine the immunogen sequence used to generate the antibody

  • The immunogen for FLRT2 antibodies should target unique regions not present in related proteins

  • For example, some antibodies are generated using recombinant fusion proteins containing specific amino acid sequences

• Western Blot Molecular Weight Analysis:

  • FLRT2 has an expected molecular weight of approximately 74 kDa

  • Related proteins will appear at different molecular weights (FLRT1: ~68 kDa, FLRT3: ~73 kDa)

  • Observed deviations may indicate post-translational modifications or isoforms

• Confirmatory Approaches:

  • Employ mass spectrometry for definitive protein identification

  • Use multiple antibodies targeting different epitopes of FLRT2

  • Complement with mRNA analysis using isoform-specific primers

• Cross-Reactivity Testing:

  • Test antibody against recombinant FLRT1, FLRT2, and FLRT3

  • Perform peptide competition assays with peptides derived from each family member

  • Document any cross-reactivity in experimental protocols

These approaches enable researchers to confidently identify FLRT2 specifically, minimizing misinterpretation due to antibody cross-reactivity with related proteins.

How do post-translational modifications affect FLRT2 antibody binding and experimental outcomes?

Post-translational modifications (PTMs) of FLRT2 can significantly impact antibody recognition and experimental interpretation:

• Common PTMs Affecting FLRT2:

  • Glycosylation: FLRT2 contains multiple potential N-glycosylation sites

  • Phosphorylation: May occur on serine/threonine residues

  • Proteolytic cleavage: FLRT2 can be shed from the cell surface

• Impact on Antibody Binding:

  • Epitope masking: PTMs may physically block antibody access to recognition sites

  • Conformational changes: PTMs can alter protein folding, affecting conformational epitopes

  • Molecular weight shifts: PTMs can cause band shifts in Western blots (glycosylated FLRT2 may appear at ~80-90 kDa rather than 74 kDa)

• Experimental Strategies:

  • Enzymatic treatment: Pre-treat samples with glycosidases or phosphatases to remove specific PTMs

  • Use multiple antibodies targeting different epitopes

  • Document any unexpected banding patterns and correlate with potential PTMs

  • Consider using antibodies specifically designed to recognize modified forms of FLRT2

• Interpretation Considerations:

  • Different tissues/cell types may exhibit distinct FLRT2 PTM patterns

  • Pathological conditions may alter PTM profiles

  • Developmental stages may show dynamic changes in FLRT2 modifications

Understanding these factors allows researchers to accurately interpret results and avoid misattribution of signals to non-specific binding or experimental artifacts.

What is the relationship between free light chains (FLCs) and FLRT2 in immune research?

The relationship between free light chains (FLCs) and FLRT2 in immune research represents an emerging area of investigation that connects immunoglobulin biology with cell adhesion molecules:

• Conceptual Connections:

  • Free light chains (κ and λ) are immunoglobulin components produced during antibody synthesis

  • FLCs are elevated in conditions associated with immune hyperactivation

  • FLRT2, as a cell adhesion molecule, may interact with immune cells during inflammatory processes

• Potential Research Intersections:

  • Both FLCs and FLRT2 have been investigated in inflammatory contexts

  • Recent research has shown elevated κFLC and λFLC levels in COVID-19 patients, suggesting immune hyperactivation

  • FLRT2 expression may be altered in tissues during inflammatory responses

• Methodological Considerations:

  • When studying both molecules, researchers should:

    • Use specific detection methods for each (e.g., turbidimetric methods for FLCs, immunoassays for FLRT2)

    • Consider potential temporal relationships in expression patterns

    • Investigate potential functional interactions through co-localization or co-immunoprecipitation studies

• COVID-19 Research Context:

  • FLCs have been evaluated as potential biomarkers in COVID-19

  • The κ:λ ratio differs significantly between COVID-19 patients and healthy controls

  • Future research may investigate whether FLRT2 expression correlates with FLC levels in inflammatory conditions

While direct functional relationships between FLCs and FLRT2 remain to be fully elucidated, both represent important areas for immunological research, particularly in the context of inflammatory and infectious diseases.

How should researchers address common issues with non-specific binding when using FLRT2 antibodies?

Non-specific binding is a frequent challenge when working with FLRT2 antibodies. Researchers can implement the following troubleshooting strategies:

• Optimization of Blocking Conditions:

  • Test different blocking agents (BSA, non-fat milk, normal serum)

  • Increase blocking time or concentration

  • Add 0.1-0.3% Triton X-100 to reduce hydrophobic interactions

• Antibody Dilution Optimization:

  • Perform titration experiments to find optimal antibody concentration

  • Generally start with manufacturer's recommended dilution (1:100-1:500 for WB)

  • Create dilution series to identify concentration with best signal-to-noise ratio

• Stringency Adjustments:

  • Increase salt concentration in wash buffers (150-500 mM NaCl)

  • Add 0.05-0.1% Tween-20 to wash buffers

  • Increase number and duration of wash steps

• Additional Controls:

  • Include isotype control (e.g., rabbit IgG for rabbit polyclonal antibodies)

  • Perform peptide competition assays

  • Include genetic knockdown/knockout controls when possible

• Sample Preparation Refinements:

  • Optimize protein extraction methods

  • Pre-clear lysates with Protein A/G beads

  • Filter samples to remove aggregates

These strategies should be systematically tested and documented to establish optimal conditions for specific FLRT2 detection across different experimental systems.

How can researchers interpret conflicting results when using different FLRT2 antibody clones?

When faced with conflicting results from different FLRT2 antibody clones, researchers should:

• Analyze Epitope Differences:

  • Identify the immunogen sequences used for each antibody

  • Map epitopes to different domains of FLRT2 protein

  • Consider whether epitopes might be differentially accessible in various experimental contexts

• Evaluate Validation Documentation:

  • Review validation data for each antibody

  • Assess specificity testing (Western blot, IHC, knockdown controls)

  • Consider the extent of peer-reviewed publications using each antibody

• Perform Comparative Analysis:

  • Test antibodies side-by-side under identical conditions

  • Document any differences in staining patterns, band sizes, or signal intensity

  • Consider whether differences might reveal biologically relevant information (e.g., isoforms, PTMs)

• Orthogonal Validation:

  • Complement antibody-based detection with mRNA analysis

  • Use mass spectrometry for definitive protein identification

  • Employ genetic approaches (overexpression, knockdown) to manipulate FLRT2 levels

• Results Integration Framework:

  • Develop a decision matrix based on multiple lines of evidence

  • Weight results according to validation strength

  • Consider whether discrepancies might reveal novel biological insights

By systematically analyzing and addressing discrepancies, researchers can determine whether conflicting results reflect technical limitations or genuine biological complexity.

What approaches should be used to quantify FLRT2 expression levels across different experimental conditions?

Accurate quantification of FLRT2 expression requires rigorous methodological approaches:

• Western Blot Quantification:

  • Use appropriate loading controls (β-actin, GAPDH, tubulin)

  • Ensure linear detection range (avoid saturated signals)

  • Employ densitometry software with background subtraction

  • Normalize FLRT2 signal to loading control

  • Report results as fold-change relative to control conditions

• Immunohistochemistry/Immunofluorescence Quantification:

  • Use consistent image acquisition settings

  • Quantify staining intensity using appropriate software (ImageJ, CellProfiler)

  • Establish clear criteria for positive vs. negative staining

  • Count positive cells as percentage of total cell population

  • Consider using automated image analysis to reduce bias

• ELISA/Immunoassay Quantification:

  • Generate standard curves using recombinant FLRT2

  • Ensure samples fall within linear range of detection

  • Run technical replicates (minimum triplicate)

  • Include quality controls on each plate

  • Calculate concentration using four-parameter logistic regression

• Statistical Analysis Considerations:

  • Perform power analysis to determine appropriate sample size

  • Test data for normality before selecting parametric/non-parametric tests

  • Account for multiple comparisons when testing across numerous conditions

  • Report effect sizes alongside p-values

  • Include confidence intervals for all quantitative measurements

• Integrated Multi-Method Approach:

  • Combine protein and mRNA quantification

  • Correlate results across different quantification methods

  • Document any discrepancies and potential explanations

These methodological approaches ensure robust, reproducible quantification of FLRT2 across experimental conditions while minimizing technical artifacts and bias.

How might FLRT2 antibodies contribute to understanding inflammatory and immune responses?

FLRT2 antibodies offer promising tools for investigating potential roles in inflammatory and immune processes:

• Cellular Localization During Immune Activation:

  • FLRT2 antibodies can track protein redistribution during immune cell activation

  • Immunofluorescence studies may reveal FLRT2 dynamics at immune synapses

  • Co-localization with immune receptors may suggest functional interactions

• Expression Pattern Analysis:

  • FLRT2 expression might be altered in inflammatory conditions

  • Antibodies enable comparative studies across normal vs. inflamed tissues

  • Potential correlation with inflammatory biomarkers like FLCs, which show elevated levels during immune hyperactivation

• Functional Studies:

  • Blocking antibodies against FLRT2 could reveal roles in immune cell migration

  • Phospho-specific antibodies might detect activation-dependent modifications

  • Proximity ligation assays could identify novel FLRT2 interaction partners in immune cells

• Translational Research Applications:

  • COVID-19 research has demonstrated altered immune markers including FLCs

  • FLRT2 antibodies could investigate potential changes in adhesion molecule expression during infection

  • Correlation studies between FLRT2 expression and clinical outcomes might identify prognostic biomarkers

These approaches represent emerging directions that leverage FLRT2 antibodies to expand understanding of inflammatory processes and immune regulation.

What methodological considerations are important when using FLRT2 antibodies in primary cell cultures versus established cell lines?

Working with FLRT2 antibodies across different cellular systems requires specific methodological adaptations:

• Primary Cell Considerations:

  • Higher variability in FLRT2 expression between donors necessitates larger sample sizes

  • Shorter culture durations may better preserve native FLRT2 expression patterns

  • Gentle fixation protocols (2-4% PFA, 10 minutes) help preserve epitope accessibility

  • Background autofluorescence is often higher, requiring careful negative controls

  • Donor characteristics (age, sex, disease status) should be documented and considered in analysis

• Cell Line Considerations:

  • Verify FLRT2 expression in target cell line through preliminary Western blot

  • Consider potential alterations in expression/localization due to immortalization

  • Higher passage numbers may alter FLRT2 expression profiles

  • Consistent culture conditions are essential for reproducible results

  • CRISPR-engineered FLRT2 knockout cell lines provide valuable negative controls

• Comparative Protocol Adjustments:

  Parameter	Primary Cells	Cell Lines
  Antibody concentration	Often higher (1:50-1:200)	Often lower (1:200-1:500)
  Fixation	Milder conditions	Standard protocols
  Permeabilization	Gentler detergents	Standard Triton X-100
  Background blocking	More stringent	Standard protocols
  Controls	Donor-matched negative controls	Isotype controls

• Validation Approaches:

  • Confirm antibody performance in each new cell system

  • Compare staining patterns between primary cells and corresponding cell lines

  • Document any discrepancies and adjust protocols accordingly

These methodological considerations ensure optimal FLRT2 detection across diverse cellular systems while accounting for their inherent biological differences.

How can researchers integrate FLRT2 antibody-based techniques with emerging single-cell technologies?

Integrating FLRT2 antibody techniques with single-cell technologies represents an innovative frontier:

• Single-Cell Proteomics Integration:

  • Conjugate FLRT2 antibodies with metal isotopes for mass cytometry (CyTOF)

  • Include FLRT2 in antibody panels for single-cell Western blot platforms

  • Develop microfluidic antibody capture assays for FLRT2 detection

• Spatial Transcriptomics Correlation:

  • Perform sequential immunofluorescence with FLRT2 antibodies followed by spatial transcriptomics

  • Correlate protein localization with mRNA expression patterns

  • Integrate data using computational approaches to map FLRT2 protein-mRNA relationships

• High-Throughput Imaging Applications:

  • Employ FLRT2 antibodies in imaging mass cytometry for tissue analysis

  • Develop multiplexed immunofluorescence panels including FLRT2

  • Use cyclic immunofluorescence to correlate FLRT2 with dozens of other markers

• Single-Cell Functional Assays:

  • Combine FLRT2 antibody labeling with single-cell migration assays

  • Correlate FLRT2 expression with individual cell behaviors

  • Employ live-cell imaging with non-blocking fluorescently-labeled FLRT2 antibody fragments

• Computational Analysis Frameworks:

  • Develop algorithms to integrate FLRT2 protein data with single-cell transcriptomics

  • Create visualization tools for multi-parameter FLRT2 analyses

  • Implement machine learning approaches to identify FLRT2-associated cellular phenotypes

These innovative approaches expand the utility of FLRT2 antibodies beyond traditional applications, enabling comprehensive analysis of FLRT2 biology at unprecedented resolution.